Beam Therapeutics Earnings Reports

Beam Therapeutics reported a net loss of $90.4 million for Q4 2024, with cash, cash equivalents, and marketable securities totaling $850.7 million. The company achieved its adult enrollment target in the BEACON trial and anticipates key milestones for its BEAM-101, ESCAPE, BEAM-301, and BEAM-302 programs.

Beam Therapeutics reported its third quarter 2024 financial results, highlighting progress in hematology and liver genetic disease programs. Noteworthy achievements include the upcoming presentation of BEAM-101 clinical data and preclinical data for ESCAPE at the ASH Annual Meeting, the completion of dosing for the first cohort in the BEAM-302 clinical trial, and an open IND with the FDA for BEAM-301. The company ended the quarter with $925.8 million in cash, cash equivalents, and marketable securities, expecting an operating runway into 2027.

Beam Therapeutics reported progress in its clinical portfolio, including the FDA clearance of the IND application for BEAM-301 and enrollment advancements in the BEACON trial of BEAM-101. The company ended the quarter with $1.0 billion in cash, cash equivalents and marketable securities, expecting an operating runway into 2027. Net loss for the quarter was $91.1 million, or $1.11 per share.

Beam Therapeutics reported a net loss of $98.7 million for Q1 2024 and ended the quarter with $1.1 billion in cash, cash equivalents, and marketable securities. The company is progressing with its BEACON Phase 1/2 trial of BEAM-101 in severe sickle cell disease and expects to initiate a Phase 1/2 trial for BEAM-302 in AATD in the first half of 2024.

Beam Therapeutics reported a net income of $142.8 million for the fourth quarter of 2023, with cash, cash equivalents, and marketable securities totaling $1.2 billion. The company anticipates key milestones for BEAM-101, ESCAPE, BEAM-301, and BEAM-302, and expects cash runway to support operating plans into 2027.

Beam Therapeutics reported a net loss of $96.1 million for Q3 2023, with R&D expenses at $100.0 million and G&A expenses at $25.4 million. Lilly acquired Beam’s opt-in rights to Verve Therapeutics’ base editing cardiovascular programs for up to $600 million. The company's cash, cash equivalents and marketable securities were $1.0 billion as of September 30, 2023, and anticipates operating runway into the second half of 2026.

Beam Therapeutics reported progress in its clinical trials for BEAM-101 and BEAM-201, and accelerated the development of BEAM-302, expecting a regulatory filing in Q1 2024. The company is well-capitalized with $1.1 billion in cash, cash equivalents and marketable securities. Net loss was $82.8 million, or $1.08 per share, compared to $72.0 million, or $1.02 per share for the second quarter of 2022.

Beam Therapeutics reported its first quarter 2023 financial results, highlighting progress in its BEACON clinical trial, the upcoming BEAM-201 clinical trial, and advancements in its in vivo programs BEAM-301 and BEAM-302. The company's cash position remains strong at $1.1 billion. A net loss of $96.5 million was reported, with R&D expenses increasing to $99.6 million.

Beam Therapeutics reported its Q3 2022 financial results with a net loss of $109.6 million, or $1.56 per share. The company ended the quarter with $1.1 billion in cash, cash equivalents and marketable securities. Portfolio updates included patient recruitment underway in the BEACON clinical trial of BEAM-101 and IND-enabling studies underway for BEAM-301.

Beam Therapeutics reported its Q2 2022 financial results, including cash, cash equivalents and marketable securities of $1.2 billion. The company is on track for patient enrollment in the BEACON Phase 1/2 trial of BEAM-101 in the second half of 2022. The IND for BEAM-201 was submitted to the FDA but is currently on clinical hold.

Beam Therapeutics reported its Q1 2022 financial results, highlighting advancements in its pipeline, including progress with BEAM-101, BEAM-102, and BEAM-201 programs, and the initiation of IND-enabling studies for BEAM-301. The company ended the quarter with $1.2 billion in cash, cash equivalents, and marketable securities.

Beam Therapeutics reported a strong cash position of $1.2 billion, including a $300 million upfront payment from Pfizer, to support milestones across ex vivo and in vivo base editing programs. The company is advancing its sickle cell disease strategy with planned clinical trials for BEAM-101 and BEAM-102.

Beam Therapeutics announced the FDA clearance of its IND application for BEAM-101, initiated IND-enabling studies for BEAM-102, and continued progress on BEAM-201. They also executed a non-exclusive option and license agreement with Sana Biotechnology for Cas12b.

Beam Therapeutics reported progress in advancing its base editing programs, remaining on track to submit the first investigational new drug (IND) for BEAM-101 in the second half of 2021. They initiated IND-enabling studies for BEAM-201 and expanded their collaboration network with Apellis. The company's cash, cash equivalents, and marketable securities were $615.3 million as of June 30, 2021.

Beam Therapeutics reported a net loss of $201.6 million, or $3.35 per share, for the first quarter of 2021. The company's cash, cash equivalents, and marketable securities were $503.5 million as of March 31, 2021. Beam is on track to submit its first Investigational New Drug (IND) application for BEAM-101 in the second half of 2021.

Beam Therapeutics reported a net loss of $34.5 million, or $0.69 per share, for the third quarter of 2020. The company's cash, cash equivalents, and marketable securities were $202.2 million as of September 30, 2020. BEAM-201 was named as a development candidate for T-ALL treatment.

Beam Therapeutics reported pipeline updates, recent business highlights and second quarter 2020 financial results, highlighted by the naming of BEAM-101 and BEAM-102 as development candidates for sickle cell disease.

Beam Therapeutics reported its Q1 2020 financial results, highlighting a net loss of $31.7 million, or $1.03 per share, and a cash position of $253.4 million. The company also presented promising data from its base editing programs at the ASGCT Annual Meeting, including in vivo proof of concept for alpha-1 antitrypsin deficiency and potential best-in-class approaches for sickle cell disease.